BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 34290084)

  • 1. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
    Kang SS; Ahn EH; Zhang Z; Liu X; Manfredsson FP; Sandoval IM; Dhakal S; Iuvone PM; Cao X; Ye K
    EMBO J; 2018 Jun; 37(12):. PubMed ID: 29769405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model.
    Lu J; Sun F; Ma H; Qing H; Deng Y
    Biochem Biophys Res Commun; 2015 Sep; 464(4):988-993. PubMed ID: 26192120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates.
    Arawaka S; Sato H; Sasaki A; Koyama S; Kato T
    Acta Neuropathol Commun; 2017 Jun; 5(1):48. PubMed ID: 28619113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats.
    Thomsen MB; Ferreira SA; Schacht AC; Jacobsen J; Simonsen M; Betzer C; Jensen PH; Brooks DJ; Landau AM; Romero-Ramos M
    Neurobiol Dis; 2021 Feb; 149():105229. PubMed ID: 33352233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.
    Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M
    J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
    Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
    CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
    Luk KC; Kehm V; Carroll J; Zhang B; O'Brien P; Trojanowski JQ; Lee VM
    Science; 2012 Nov; 338(6109):949-53. PubMed ID: 23161999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
    Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
    J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP
    Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J
    J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
    Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
    Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.